Carl Zeiss Meditec AG : Carl Zeiss Meditec records positive first quarter

Thursday, 14. February 2013 07:02

Carl Zeiss Meditec AG / Carl Zeiss Meditec AG : Carl Zeiss Meditec records positive first quarter . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Carl Zeiss Meditec records positive first quarter

Revenue up four per cent, Microsurgery and Surgical Ophthalmology are strong

Irrespective of the difficult underlying global economic conditions, Carl Zeiss Meditec AG closed the first quarter of financial year 2012/2013 with solid earnings. The medical technology company's revenues were up by four per cent to EUR 219.0m compared to the same quarter of the previous year; profitability and earnings per share were also up.

JENA, 14 February 2013
In the first three months of the new financial year, the company recorded revenues of EUR 219.0m (previous year: EUR 210.3m) and EBIT of EUR 31.2m (previous year: EUR 28.3m). The EBIT margin improved from 13.4 per cent to 14.3 per cent; earnings per share increased compared to the same quarter of the previous year from EUR 0.21 to EUR 0.29. The strategic business units exhibited very different performance. 
"Our positive overall growth is due, in particular, to the balanced and broad footing of our business," commented Dr. Ludwin Monz, Carl Zeiss Meditec AG's President and CEO. "In view of the reserved economic growth in many global markets, the investments we have made in Asia are really paying off now." 

Revenue by business unit 
The Microsurgery strategic business unit (SBU) continued to be profitable and displayed strong growth in the first quarter. Its revenues were up by 10.3 per cent.

In contrast, revenues in the Ophthalmic Systems SBU were down by 6.9 per cent with a positive contribution to earnings. As a result of a comprehensive change of models at the end of the year, revenues for Optical Coherence Tomography (OCT) decreased. At the same time, a higher level of competition was increasingly noticeable in some segments of this business unit. 
Revenue in the Surgical Ophthalmology SBU grew by 21.2 per cent. In particular, a new product line for premium intraocular lenses contributed to the positive development. 

Revenue by region
In the EMEA region (Europe, Middle East, Africa) revenues were up by 1.2 per cent with continued, highly non-uniform growth. Germany has continued to be the main sales driver and enjoyed positive growth; the Russian market also proved its continued strength, whereas the most of the other countries recorded reserved or negative growth.
Performance in the Americas region was weak during the quarter. Excellent growth rates in South America were counteracted by negative figures on the US market.
Once again, the APAC (Asia/Pacific) region recorded substantially double-digit growth of 14.1 per cent. China, Japan and Australia made particularly strong contributions to this growth.

In the words of Ludwin Monz, Carl Zeiss Meditec is, on the whole, positioned robustly enough to also deal well with a weaker global economy. "A slower pace of growth will also be reflected in our business over the longer term. However, as things stand today, we are sticking to our targets through to 2015." 

Revenue by strategic business unit

Figures in € '000 3 Months 2011/2012 3 Months 2012/2013 Change from previous year
Ophthalmic Systems 90,700 84,421 - 6.9%
Surgical Ophthalmology 24,325 29,472 + 21.2%
Microsurgery 95,316 105,106 + 10.3%

Revenue by region

Figures in € '000 3 Months 2011/2012 3 Months 2012/2013 Change from previous year
EMEA 75,271  76,209 + 1.2%
Americas 73,897 72,973 - 1.3%
Asia/Pacific region 61,173 69,817 + 14.1%


Press contacts:
Jann Gerrit Ohlendorf, Corporate Communications, Carl Zeiss Meditec AG
Phone 03641 220-331, E-Mail:

Contact for investors:
Henriette Meyer, Investor Relations, Carl Zeiss Meditec AG
Phone 03641 220-106, E-Mail:

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2011/2012 (ended 30 September) the Group's more than 2,400 employees generated revenue of almost € 862 million. The head office of Carl Zeiss Meditec is in Jena, Germany.

The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
Fore more than 160 years Carl Zeiss has been contributing to the progress of technology on the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, improving the quality of life for many people. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For more information visit our website at:


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Carl Zeiss Meditec AG via Thomson Reuters ONE


--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN: 531370;ISIN: DE0005313704;Index:Prime All Share,TECH All Share,TecDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Related Links: Carl Zeiss Meditec AG
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.